Long term outcomes for patients treated with half-fluence photodynamic therapy for chronic central serous chorioretinopathy: a case series.

A case series was used to evaluate the efficacy of half-fluence photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSCR). Patients were treated with standard-dose verteporfin and half-fluence PDT. Totally 13 eyes from 11 patients were included. The mean patient age was 52.0y. There was a mean reduction in central retinal thickness of 107.0 microns. Totally 7/13 eyes (53.8%) achieved resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) scan after 1 treatment with PDT. Four eyes had further treatment with PDT; of these 1 eye achieved resolution of SRF. Seven of the 13 eyes (53.8%) achieved an improvement of more than 5 ETDRS letters. One patient experienced acute macula oedema 1d post PDT treatment. These results support the hypothesis that half-fluence PDT can have a positive effect in chronic CSCR for a gain in visual acuity and reduction in sub-retinal fluid. Acute macula oedema is a rare but potential adverse effect of half-fluence PDT.

[1]  Chi-Hsien Peng,et al.  COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY , 2017, Retina.

[2]  Zaid Mammo,et al.  INCIDENCE OF ACUTE EXUDATIVE MACULOPATHY AFTER REDUCED-FLUENCE PHOTODYNAMIC THERAPY , 2017, Retinal cases & brief reports.

[3]  M. Brelen,et al.  A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. , 2016, American journal of ophthalmology.

[4]  S. Fonseca,et al.  Half-dose photodynamic therapy for chronic central serous chorioretinopathy: Efficacy and safety outcomes in real world. , 2016, Photodiagnosis and photodynamic therapy.

[5]  Mahesh Gopalakrishnan,et al.  Half-fluence photodynamic therapy in chronic central serous chorioretinopathy , 2016 .

[6]  K. Falavarjani,et al.  Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy , 2016, Journal of ophthalmic & vision research.

[7]  Y. Mizutani,et al.  One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. , 2015, Ophthalmology.

[8]  U. Behera,et al.  Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. , 2015, American journal of ophthalmology.

[9]  Yong-Kyu Kim,et al.  Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[10]  D. Lin,et al.  Comparison of the optical coherence tomographic characters between acute Vogt-Koyanagi-Harada disease and acute central serous chorioretinopathy , 2014, BMC Ophthalmology.

[11]  W. Chang,et al.  Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy , 2013, Eye.

[12]  Jason Noble,et al.  Central serous chorioretinopathy: update on pathophysiology and treatment. , 2013, Survey of ophthalmology.

[13]  C. Glittenberg,et al.  HALF-FLUENCE PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY , 2013, Retina.

[14]  J. Cunha-Vaz,et al.  PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A 4-Year Follow-up Study , 2013, Retina.

[15]  A. Rouvas,et al.  Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy , 2012, European journal of ophthalmology.

[16]  A. Al-Hinai,et al.  Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series , 2011, Oman journal of ophthalmology.

[17]  K. Park,et al.  COMPARISON OF EFFICACY AND SAFETY BETWEEN HALF-FLUENCE AND FULL-FLUENCE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY , 2011, Retina.

[18]  A. Lotery,et al.  Central serous chorioretinopathy: an update on pathogenesis and treatment , 2010, Eye.

[19]  L. Yannuzzi.  Central serous chorioretinopathy: a personal perspective. , 2010, American journal of ophthalmology.

[20]  F. Boscia,et al.  Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. , 2010, American journal of ophthalmology.

[21]  Young Min Park,et al.  Fundus Autofluorescence in Acute and Chronic-recurrent Central Serous Chorioretinopathy , 2009 .

[22]  J. Kang,et al.  Chronic Central Serous Chorioretinopathy: Photodynamic Therapy , 2007 .

[23]  K. Argyle.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: A short term pilot study , 2006 .

[24]  U. Schmidt-Erfurth,et al.  Influence of treatment parameters on selectivity of verteporfin therapy. , 2006, Investigative ophthalmology & visual science.

[25]  E. Gragoudas,et al.  Experience with nontreatment of central serous choroidopathy. , 1974, Archives of ophthalmology.